African research identifies strong candidate for possible single-dose malaria cure

Compound discovered by UCT drug discovery programme selected by MMV for its potent activity against multiple points in parasite's lifecycle

2012-08-28

(Press-News.org) A recently discovered compound from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person to person, according to a research collaboration involving the Medicines for Malaria Venture (MMV), based in Switzerland, and the Drug Discovery and Development Centre (H3-D) at the University of Cape Town, South Africa. On the basis of initial results it was selected by MMV for further development – making it the first compound researched on African soil to enter preclinical development in partnership with MMV.

An African solution to save lives

Mrs Naledi Pandor, the Minister of Science & Technology, said: "This is a significant victory in the battle to alleviate the burden of disease in the subcontinent. Clearly the war on this disease is not yet won, but I am excited by the role that our excellent scientists have played in this milestone in finding a potential cure for malaria and possibly preventing its transmission. Congratulations to Professor Kelly Chibale and all involved. This is evidence of the world-class science being done in South Africa and the continent, and of the power of continental and international scientific collaboration in the multidisciplinary approaches that are essential in addressing the societal challenges of our time."

Dr Max Price, the Vice-Chancellor of UCT, said: "H3-D was founded at UCT in 2010 for this very purpose: to develop African expertise towards solving the health problems that beset the developing world. We trust this clinical candidate is the first of many contributions Professor Chibale and his team will be making to the advancement of international medicine."

H3-D identified a molecule, code named MMV390048, which was selected in July 2012 by MMV's Expert Scientific Advisory Committee for further development. The promising new compound shows potent activity against multiple points in the malaria parasite's lifecycle. This means it not only has the potential to become part of a single-dose cure for malaria but might also be able to block transmission of the parasite from person to person.

The aminopyridine series was initially identified by Griffith University scientists in Australia as part of MMV's extensive malaria screening campaign of around 6 million compounds. A team of scientists from H3-D, led by UCT Professor Kelly Chibale, further scrutinised and explored the antimalarial potential of the series. With parasitological, pharmacological and contract chemistry support from the Swiss Tropical and Public Health Institute (Switzerland), the Centre for Drug Candidate Optimization at Monash University (Australia) and Syngene (India) respectively, the H3-D team selected the most promising compounds from the series to be optimised and retested. In just 18 months the team had identified and developed a candidate suitable for preclinical development.

Equipping the next generation of African scientists

"We are very excited that this promising compound, researched by African scientists, has been selected by MMV for further development," said Professor Chibale, the Founder and Director of H3-D. "This is truly a proud day for African science and African scientists. Our team is hopeful that the compound will emerge from rigorous testing as an extremely effective medicine for malaria – a disease that accounts for 24% of total child deaths in sub-Saharan Africa. What is more, H3-D and MMV achieved MMV390048 as a clinical candidate in record time. In the process we have developed a unique model for successful technology platforms, and generic modern pharmaceutical industry expertise and skills, to discover drugs in potentially any disease area in Africa."

Dr Tim Wells, MMV's Chief Scientific Officer, said: "This is a great achievement and an excellent example of the quality of research that can be fostered in Africa. We look forward to seeing more exciting compounds emerge from Kelly's team and are proud to be collaborating with H3-D; not only is it conducting excellent science today, but it is also providing world-class training for the next generation of African scientists."

What is so unique and exciting about MMV390048

It is very potent: it displayed a complete cure of animals infected with malaria parasites in a single dose given orally, and thus has the potential to cure millions of people.

It is active against a wide panel of resistant strains of the malaria parasite.

Developing the drug has made possible the training of more than 10 local scientists and cemented a strong relationship with an international partner.

The clinical candidate is in line to enter clinical trials in late 2013.

### END

ELSE PRESS RELEASES FROM THIS DATE:

Personalized antiplatelet treatment improves outcome after PCI

2012-08-28

Munich, Germany – August 26 2012: Personalized antiplatelet treatment leads to better outcomes than standard antiplatelet treatment in patients undergoing coronary stent implantation, according to results from the MADONNA study presented at ESC Congress 2012. The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna. Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel. But measurements of platelet ...

30-day mortality after AMI drops with improved treatment

2012-08-28

Munich, Germany – August 28 2012: Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012. The analysis of four French registries from 1995 to 2010 was presented by Professor Nicolas Danchin from the Hopital Européen Georges Pompidou. Cardiologists recognize two types of myocardial infarction. The first type, ST-elevation myocardial infarction (STEMI), corresponds to the sudden, permanent occlusion of a coronary artery supplying the myocardium ...

New method: Research team analyzes stress biology in babies

2012-08-28

After waking up, the concentration of the stress hormone cortisol in saliva rises considerably; this is true not only for grown-ups but for babies as well. A research team from the Ruhr-Universität Bochum and from Basel has reported this finding in the journal Psychoneuroendocrinology. "This gives us a new, non-invasive and uncomplicated possibility to already research the activity of the stress system during infancy," Prof. Dr. Gunther Meinlschmidt, of the Clinic of Psychosomatic Medicine and Psychotherapy at the LWL University Hospital of the RUB, said. The information ...

Ten year decline in ischemic stroke after AMI

2012-08-28

Munich, Germany – August 28 2012: The risk of ischemic stroke one year after acute myocardial infarction (AMI) dropped by 21% over a ten year period, according to research presented at ESC Congress 2012. The analysis of data from two Swedish registries was presented by Dr Anders Ulvenstam, and suggests that the reduction is due to improvements in AMI care. Ischemic stroke is a well known, relatively rare but potentially devastating complication following myocardial infarction. It can lead to severe neurological handicap and death for the patient and it is associated with ...

Global platelet reactivity identifies high risk ACS patients

2012-08-28

Munich, Germany – August 26 2012: Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at the ESC Congress today. The results from the RECLOSE 2-ACS study were presented by Dr Rossella Marcucci from Italy. The Responsiveness to Clopidogrel and Stent thrombosis 2 – ACS (RECLOSE 2-ACS) study is a prospective, observational, referral center cohort study of 1,789 patients with acute coronary syndromes undergoing percutaneous coronary ...

The raccoon spreads dangerous diseases as it invades Europe

2012-08-28

Furry, agile, intelligent and voracious: the raccoon is far from being a cuddly toy, which is what many people believe when they get one as a pet. It is more like an invader that escapes and is able to adapt and survive in new habitats. According to a study, its expansion across Spain and Europe is bringing infectious and parasitic diseases like rabies. This puts the health of native species and people at risk. Originating in North America, the raccoon (Procyon lotor) is an invasive species that has established itself in Europe due to hunting and the fur trade along with ...

How 'beige' fat makes the pounds melt away

2012-08-28

The numbers of obese people are climbing steeply all over the world – with obvious major consequences for their health. Due to excess food intake and a lack of physical activity, but also due to genetic factors, the risk for overweight people dying from diseases like coronary heart disease, diabetes und atherosclerosis increases. "The body's fat reserves are actually used as a place to store energy that allows surviving lean times," says Prof. Dr. Alexander Pfeifer, Director of the Institute of Pharmacology and Toxicology of the University of Bonn. "But nowadays, hardly ...

Capturing movements of actors and athletes in real time with conventional video cameras

2012-08-28

This press release is available in German.In the computer graphics (CG) animated comedy "Ted," which is running now in the cinemas, Ted is a teddy bear who came to life as the result of a childhood wish of John Bennett (Mark Wahlberg) and has refused to leave his side ever since. CG Animated characters like "Ted" have become a standard of Hollywood's movie productions since the blockbuster "Avatar" with its blue-skinned computer-animated characters won three Oscars and brought in three billion US dollars, digital animated characters have become a standard of Hollywood's ...

ESC Acute Cardiovascular Care Association launched

2012-08-28

ACCA was previously the ESC Working Group on Acute Cardiac Care. Today it becomes one of six ESC Associations, whose presidents are invited to ESC Board meetings. "It will be easier to inform the ESC Board about the activities of the association," said Professor Christiaan Vrints (Belgium), outgoing chairman of the Working Group on Acute Cardiac Care. "We will also have a bigger impact on the policies and the development of the ESC as an organisation." The Working Group on Acute Cardiac Care had the largest and fastest growing membership of ESC working groups. Over the ...

Study of tribe could help find East Asian skin color genes

2012-08-28

Genetic investigation of a Malaysian tribe may tell scientists why East Asians have light skin but lower skin cancer rates than Europeans, according to a team of international researchers. Understanding the differences could lead to a better way to protect people from skin cancer. While the genetics of skin color is largely unknown, past research using zebrafish by Penn State College of Medicine's Keith Cheng, M.D., Ph.D., identified the gene in Europeans that differs from West Africans and contributes to a lighter skin color. Mutations in the genes SLC24A5 and SLC45A2 ...